CLNN

Clene Inc. (CLNN) | Rumor.io

Clene

CLNN

Attention (50-day avg)0%

Attention rank (50-day avg)#1,973

Bullish sentiment (50-day avg)80%

Price to earnings ratio-1.54

Market capitalization57.7M

Earnings per share-3.35

Dividend yield (TTM)—

Revenue (annual)200K

Net income (annual)-26.2M

Social

What share of all stock conversation is about CLNN?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% 0	0% +0	0% 0

Sep 15

Clene Inc. ($CLNN) is receiving a $4 million direct offering from investors, including its Chairman and CEO, indicating confidence in the FDA's acceptance of the company's NDA.
The company's recent financials and risk profile are a concern, with the market capitalization not properly reflecting the risk-reward profile of the candidate/pipeline.
Clene Announces a $4 million registered direct offering, with 1,219,513 shares to be sold at a purchase price of $3.28 per share to existing shareholders, including insiders.

Generated by AI

Sentiment

Of the messages about CLNN that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	100% 0	87.8% +14.24	82.71% -6.76
Bearish	0%	0% 0	12.2% -14.24	17.29% +6.76

Bullish· May 4

$CLNN is expected to have several positive catalysts in the coming week, including its 1Q earnings release, CEO presentation at the Emerging Growth conference, and 1Q ER Conference Call with analysts.
The stock has significant upside potential, with a target price of $31.00 and a potential price of $800/share for ALS alone, driven by the FDA's thumbs up for the company's ALS therapy.
The stock is experiencing increased volume and price momentum, with a recent FDA meeting clearing the path for an accelerated approval NDA in ALS, leading to a +30% premarket jump to $7.98.

Bearish· May 6

$CLNN may reverse to its 52-week high of $13.50 due to ALS news.
The stock's price is expected to drop to $8.00.
Short positions may be a bad idea due to the stock's potential to surge.

Generated by AI

Topics

Of the messages about CLNN that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	62.92%	50.89%
Analysts	—	0%	12.36%	15.23%
Macro	—	0%	12.36%	1.52%
Technical Analysis	—	0%	12.36%	28.93%
Controversies	—	0%	0%	2.16%
Earnings	—	0%	0%	1.27%

Announcements· Apr 17

Clene Inc. was awarded a $45.1 million grant from the National Institute of Neurological Disorders and Stroke to support a new treatment for ALS.
Clene reported new data from a drug development program, but details are not specified.
HC Wainwright & Co. reiterated a Buy rating and $7 price target on Clene, potentially driving positive investor sentiment.

Technical Analysis· Jul 13

*CLNN* formed a cup and handle pattern, with a target price of 26.
A strong short setup was entered on *CLNN*, but it failed to break through VWAP and hold a retest, making it a poor long setup.
*CLNN* has formed a double dip, flying doji formation with a target price of 26+, and is showing healthy profit taking on a technical breakout.

Generated by AI

Community

Of the messages about CLNN, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	100%	84.73%	72.84%
Newcomers	0%	0%	15.27%	27.16%

Regulars· Sep 15

$CLNN's $4 million direct offering from investors, including its Chairman and CEO, indicates confidence in the FDA acceptance of the company's NDA.
The company's recent financials and market cap ($40M) are a major concern, but the risk of NDA rejection and lack of approval for CNM-Au8 is a risk for all preclinical bios with a mature pipeline candidate.
With 100x upside potential, $CLNN could be an opportunity for investors with risk tolerance, especially if approved, with a reasonable price target (PT) yet to be determined.

Newcomers· May 5

The best performer on the BullAlert Daily Wrap was $CLNN, which rose by 25% and had a win rate of 58%.
$CLNN is looking good on the 4-hour chart, with a key support level at 6.1-6.55 and a potential next key level to test at 8.7-9.15.
A $7 million direct offering to a single investor is likely to boost Clene Inc.'s immediate cash position, which may be followed by additional interest from other investors prior to the NDA submission in 3Q.

Generated by AI

News

Analysts’ Top Consumer Goods Picks: Kimberly Clark (KMB), Clene (CLNN)

Tipranks Press Release.

1mo agoThe Globe and Mail

Clene Eyes Q4 NDA for ALS Drug After FDA-Requested Biomarker Analyses

Clene (NASDAQ:CLNN) is preparing to submit a New Drug Application, or NDA, seeking accelerated approval for CNM-Au8 in amyotrophic lateral sclerosis, or ALS, after completing additional analyses requested by the U.S. Food and Drug Administration, President and CEO Rob Etherington said in an intervie

1mo agoYahoo Finance

Clene at Emerging Growth Conference: FDA path takes shape for ALS drug

1mo agoInvesting.com

Also Discussed

Investors talking about CLNN also mention

#	Name	Attention
1	Amylyx Pharmaceuticals, Inc.AMLX	0%+0
2	BCLI - Brainstorm Cell Therapeutics Inc.	——
3	Pliant Therapeutics Inc.PLRX	0%0
4	CARV - Carver Bancorp, Inc.	——
5	NeuroSense Therapeutics Ltd.NRSN	0%0
6	United Maritime CorporationUSEA	0%0
7	Kiora Pharmaceuticals Inc.KPRX	0%0
8	NRx Pharmaceuticals, Inc.NRXP	0%-0.01
9	AerSale CorporationASLE	0%0
10	CRTD - Creatd, Inc.	——

Clene Inc.

Consumer Defensive
Packaged Foods

Clene Inc. is a clinical-stage biopharmaceutical company focused on developing clean-surfaced nanotechnology therapeutics for neurodegenerative diseases. Clene Inc. develops oral nanotechnology-based drug candidates designed to support neuronal health and function, with programs centered on conditions such as amyotrophic lateral sclerosis, Parkinson’s disease, and multiple sclerosis. Its current portfolio includes investigational therapies and related platform technologies aimed at improving mitochondrial function, protecting neurons, and supporting remyelination. The company also operates activities in dietary supplements, leveraging its nanocrystal manufacturing capabilities to produce low-concentration supplement products. Headquartered in Salt Lake City, Utah, Clene Inc. plays a specialized role in the pharmaceutical market by advancing novel approaches for central nervous system disorders and related neurological conditions.

Website

Location

6550 South Millrock Drive

Salt Lake City, UT, 84121

United States

Social

What share of all stock conversation is about CLNN?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% 0	0% +0	0% 0

Sep 15

Clene Inc. ($CLNN) is receiving a $4 million direct offering from investors, including its Chairman and CEO, indicating confidence in the FDA's acceptance of the company's NDA.
The company's recent financials and risk profile are a concern, with the market capitalization not properly reflecting the risk-reward profile of the candidate/pipeline.
Clene Announces a $4 million registered direct offering, with 1,219,513 shares to be sold at a purchase price of $3.28 per share to existing shareholders, including insiders.

Generated by AI

Sentiment

Of the messages about CLNN that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	100% 0	87.8% +14.24	82.71% -6.76
Bearish	0%	0% 0	12.2% -14.24	17.29% +6.76

Bullish· May 4

$CLNN is expected to have several positive catalysts in the coming week, including its 1Q earnings release, CEO presentation at the Emerging Growth conference, and 1Q ER Conference Call with analysts.
The stock has significant upside potential, with a target price of $31.00 and a potential price of $800/share for ALS alone, driven by the FDA's thumbs up for the company's ALS therapy.
The stock is experiencing increased volume and price momentum, with a recent FDA meeting clearing the path for an accelerated approval NDA in ALS, leading to a +30% premarket jump to $7.98.

Bearish· May 6

$CLNN may reverse to its 52-week high of $13.50 due to ALS news.
The stock's price is expected to drop to $8.00.
Short positions may be a bad idea due to the stock's potential to surge.

Generated by AI

Topics

Of the messages about CLNN that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	62.92%	50.89%
Analysts	—	0%	12.36%	15.23%
Macro	—	0%	12.36%	1.52%
Technical Analysis	—	0%	12.36%	28.93%
Controversies	—	0%	0%	2.16%
Earnings	—	0%	0%	1.27%

Announcements· Apr 17

Clene Inc. was awarded a $45.1 million grant from the National Institute of Neurological Disorders and Stroke to support a new treatment for ALS.
Clene reported new data from a drug development program, but details are not specified.
HC Wainwright & Co. reiterated a Buy rating and $7 price target on Clene, potentially driving positive investor sentiment.

Technical Analysis· Jul 13

*CLNN* formed a cup and handle pattern, with a target price of 26.
A strong short setup was entered on *CLNN*, but it failed to break through VWAP and hold a retest, making it a poor long setup.
*CLNN* has formed a double dip, flying doji formation with a target price of 26+, and is showing healthy profit taking on a technical breakout.

Generated by AI

Community

Of the messages about CLNN, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	100%	84.73%	72.84%
Newcomers	0%	0%	15.27%	27.16%

Regulars· Sep 15

$CLNN's $4 million direct offering from investors, including its Chairman and CEO, indicates confidence in the FDA acceptance of the company's NDA.
The company's recent financials and market cap ($40M) are a major concern, but the risk of NDA rejection and lack of approval for CNM-Au8 is a risk for all preclinical bios with a mature pipeline candidate.
With 100x upside potential, $CLNN could be an opportunity for investors with risk tolerance, especially if approved, with a reasonable price target (PT) yet to be determined.

Newcomers· May 5

The best performer on the BullAlert Daily Wrap was $CLNN, which rose by 25% and had a win rate of 58%.
$CLNN is looking good on the 4-hour chart, with a key support level at 6.1-6.55 and a potential next key level to test at 8.7-9.15.
A $7 million direct offering to a single investor is likely to boost Clene Inc.'s immediate cash position, which may be followed by additional interest from other investors prior to the NDA submission in 3Q.

Generated by AI

Clene

Social

Sep 15

Bullish· May 4

Bearish· May 6

Announcements· Apr 17

Technical Analysis· Jul 13

Regulars· Sep 15

Newcomers· May 5

Clene raises $4 million from insiders to fund operations

Clene prices $4M registered direct offering at $3.28 per share

Clene at cantorfitzgerald global healthcare conference: ALS drug nears filing

Analysts’ Top Consumer Goods Picks: Kimberly Clark (KMB), Clene (CLNN)

Clene Eyes Q4 NDA for ALS Drug After FDA-Requested Biomarker Analyses

Clene at Emerging Growth Conference: FDA path takes shape for ALS drug

Also Discussed

Clene Inc.

Company Information

Location

Clene raises $4 million from insiders to fund operations

Clene prices $4M registered direct offering at $3.28 per share

Clene at cantorfitzgerald global healthcare conference: ALS drug nears filing

Analysts’ Top Consumer Goods Picks: Kimberly Clark (KMB), Clene (CLNN)

Clene Eyes Q4 NDA for ALS Drug After FDA-Requested Biomarker Analyses

Clene at Emerging Growth Conference: FDA path takes shape for ALS drug

Also Discussed

Social

Sep 15

Bullish· May 4

Bearish· May 6

Announcements· Apr 17

Technical Analysis· Jul 13

Regulars· Sep 15

Newcomers· May 5